Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 7, 2001, Pages 2173-2176

  Jordan, H L ^a   Pereira, A S ^a   Cohen, M S ^a   Kashuba, A D M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NUCLEOSIDE ANALOG; ZIDOVUDINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CAT; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; HUMAN; MALE; MALE GENITAL SYSTEM; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SEMINAL PLASMA;

ANIMALS; ANTI-HIV AGENTS; CATS; HUMANS; LAMIVUDINE; MALE; MODELS, ANIMAL; SEMEN; ZIDOVUDINE;

EID: 0034962082     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.7.2173-2176.2001     Document Type: Article

References (36)

1. Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection
2. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994
3. Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms
4. Lessons from the cat: Feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1
5. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: Implications for transmission
6. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
7. Long-term treatment of diseased, FIV-seropositive field cats with azidothymidine (AZT)
8. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms
9. AZT in the treatment of feline immunodeficiency virus infection. Part 1
10. AZT in the treatment of feline immunodeficiency virus infection. Part 2
11. Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats
12. Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus
13. Concurrent zidovudine concentrations in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS related complex
14. Clinical pharmacokinetics of lamivudine
15. Transmission of feline immunodeficiency virus in domestic cats via artificial insemination
16. Detection of feline immunodeficiency virus in semen from seropositive domestic cats (Felis catus)
17. Antiretroviral drug concentrations in semen: Implications for sexual transmission of HIV-1
18. Development of a new type of protease inhibitors, efficacious against FIV and HIV variants
19. Lamivudine/zidovudine as a combined formulation tablet: Bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption
20. Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses
21. Testing anti-HIV drugs in the FIV model
22. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome
23. Isolation of a T-lymphotropic virus from domestic cats with an immunodefidency-like syndrome
24. Nucleoside analogues achieve high concentrations in seminal plasma: Relationship between drug concentration and virus burden
25. Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry
26. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides
27. Effect of 3′azido-2′,3′-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats
28. Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents
29. Artificial insemination in the cat (Felis catus)
30. Anti-human immunodeficiency virus (HIV) agents are also potent selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: Development of a new method for screening of anti-FIV substances in vitro
31. Poor penetration of the male genital tract by HIV-1 protease inhibitors
32. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men
33. Antiretroviral therapy: State of the HAART
34. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection
35. Feline bone marrow transplantation: Its use in FIV-infected cats